植物乳植杆菌菌株LP28在制备提高人体免疫力的药物中的应用
The capsule form of the drug prepared by using the Lactobacillus plantarum strain LP28 solves the problem of improving human immunity and preventing the common cold in the existing technology. It significantly enhances NK cell activity and IL-12 levels, reduces the incidence of colds, alleviates upper respiratory symptoms, and maintains a stable proportion of immune cells.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SYNBIOTECH BIOTECHNOLOGY YANGZHOU CO LTD
- Filing Date
- 2026-06-05
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have failed to effectively utilize the uses of Lactobacillus plantarum strain LP28 in enhancing human immunity, promoting NK cell activity, regulating immune-related cytokines, and preventing and/or treating the common cold.
This invention provides the application of *Lactobacillus plantarum* strain LP28 in the preparation of drugs that enhance human immunity, including solid dosage forms in capsule form. Each capsule contains 5.0*10⁹ CFU of *Lactobacillus plantarum* strain LP28. Clinical trials have verified its effects in enhancing natural killer cell activity, promoting interleukin-12 expression, reducing C-reactive protein levels, alleviating the burden of upper respiratory tract symptoms, and maintaining immune balance.
It significantly enhances the cytotoxic activity of NK cells, increases IL-12 levels, reduces the incidence of the common cold, alleviates upper respiratory symptoms, maintains a stable proportion of immune cells, and enhances the immune function of middle-aged and elderly people.
Smart Images
Figure CN122398870A_ABST